Clinical Trial Update: A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for MK-1029 in allergen-challenged asthma completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• MK-1029

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Asthma | Phase 1 | Status: COMPLETED | Results posted: 2019-02-08